<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328184</url>
  </required_header>
  <id_info>
    <org_study_id>1245.41</org_study_id>
    <secondary_id>2010-023432-16</secondary_id>
    <nct_id>NCT01328184</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon</brief_title>
  <official_title>An Open-label, Two-period, Fixed-sequence Trial to Evaluate the Effect of Multiple Doses of BI 10773 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the possible effect of multiple oral doses of
      25 mg BI 10773 on the steady state pharmacokinetics of ethinylestradiol (EE) and
      levonogestrel (LNG) (Microgynon®).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Area under the concentration-time curve of ethinylestradiol in plasma at steady state over the uniform dosing interval τ.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Area under the concentration-time curve of levonorgestrel in plasma at steady state over the uniform dosing interval τ.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Maximum measured concentration of ethinylestradiol in plasma at steady state over the uniform dosing interval τ.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levonorgestrel: Maximum Measured Concentration (Cmax,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Maximum measured concentration of levonorgestrel in plasma at steady state over the uniform dosing interval τ.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Time from last dosing to the maximum measured concentration of ethinylestradiol in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Time from last dosing to the maximum measured concentration of levonorgestrel in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Apparent clearance of ethinylestradiol in the plasma at steady state after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Apparent clearance of levonorgestrel in the plasma at steady state after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Apparent volume of distribution during the terminal phase at steady state after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Apparent volume of distribution during the terminal phase at steady state after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Terminal half-life of ethinylestradiol in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Terminal half-life of levonorgestrel in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Terminal rate constant of ethinylestradiol in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Terminal rate constant of levonorgestrel in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Mean residence time of ethinylestradiol in the body at steady state after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)</measure>
    <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
    <description>Mean residence time of levonorgestrel in the body at steady state after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.</measure>
    <time_frame>Day 1 to day 17</time_frame>
    <description>Number of participants with clinically relevant abnormalities in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Tolerability</measure>
    <time_frame>Within Day 24 to Day 31</time_frame>
    <description>Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory, bad and not assessable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses of Microgynon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multiple doses of Microgynon + BI 10773</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levonorgestrel</intervention_name>
    <description>multiple doses</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levonorgestrel</intervention_name>
    <description>multiple doses</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinylestradiol</intervention_name>
    <description>multiple doses</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microgynon + BI 10773</intervention_name>
    <description>multiple doses BI 10773</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinylestradiol</intervention_name>
    <description>multiple doses</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy female subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.41.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 18, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Overall</title>
          <description>A open label, two-period, fixed sequence trial. Patients received one tablet of Microgynon once daily for 14 days, immediately followed by one tablet of Microgynon once daily plus 25mg empa once daily for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Overall</title>
          <description>A open label, two-period, fixed sequence trial. Patients received one tablet of Microgynon once daily for 14 days, immediately followed by one tablet of Microgynon once daily plus 25mg empa once daily for 7 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)</title>
        <description>Area under the concentration-time curve of ethinylestradiol in plasma at steady state over the uniform dosing interval τ.</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)</title>
          <description>Area under the concentration-time curve of ethinylestradiol in plasma at steady state over the uniform dosing interval τ.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="907" spread="24.4"/>
                    <measurement group_id="O2" value="932" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as Microgynon plus empa divided by Microgynon</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>102.82</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.58</ci_lower_limit>
            <ci_upper_limit>108.35</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)</title>
        <description>Area under the concentration-time curve of levonorgestrel in plasma at steady state over the uniform dosing interval τ.</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)</title>
          <description>Area under the concentration-time curve of levonorgestrel in plasma at steady state over the uniform dosing interval τ.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" spread="34.4"/>
                    <measurement group_id="O2" value="95.9" spread="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as Microgynon plus empa divided by Microgynon</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>101.94</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.54</ci_lower_limit>
            <ci_upper_limit>105.47</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)</title>
        <description>Maximum measured concentration of ethinylestradiol in plasma at steady state over the uniform dosing interval τ.</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)</title>
          <description>Maximum measured concentration of ethinylestradiol in plasma at steady state over the uniform dosing interval τ.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="17.6"/>
                    <measurement group_id="O2" value="96.8" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as Microgynon plus empa divided by Microgynon</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>99.22</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.40</ci_lower_limit>
            <ci_upper_limit>105.39</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levonorgestrel: Maximum Measured Concentration (Cmax,ss)</title>
        <description>Maximum measured concentration of levonorgestrel in plasma at steady state over the uniform dosing interval τ.</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Levonorgestrel: Maximum Measured Concentration (Cmax,ss)</title>
          <description>Maximum measured concentration of levonorgestrel in plasma at steady state over the uniform dosing interval τ.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.98" spread="26.1"/>
                    <measurement group_id="O2" value="8.44" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as Microgynon plus empa divided by Microgynon</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>105.81</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.47</ci_lower_limit>
            <ci_upper_limit>112.55</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)</title>
        <description>Time from last dosing to the maximum measured concentration of ethinylestradiol in plasma at steady state</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)</title>
          <description>Time from last dosing to the maximum measured concentration of ethinylestradiol in plasma at steady state</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>hours(h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="39.5" lower_limit="1.00" upper_limit="3.05"/>
                    <measurement group_id="O2" value="1.50" spread="34.2" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)</title>
        <description>Time from last dosing to the maximum measured concentration of levonorgestrel in plasma at steady state</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)</title>
          <description>Time from last dosing to the maximum measured concentration of levonorgestrel in plasma at steady state</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>hours(h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="28.1" lower_limit="0.50" upper_limit="1.52"/>
                    <measurement group_id="O2" value="1.00" spread="25.5" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)</title>
        <description>Apparent clearance of ethinylestradiol in the plasma at steady state after oral administration</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)</title>
          <description>Apparent clearance of ethinylestradiol in the plasma at steady state after oral administration</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552" spread="24.4"/>
                    <measurement group_id="O2" value="536" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)</title>
        <description>Apparent clearance of levonorgestrel in the plasma at steady state after oral administration</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)</title>
          <description>Apparent clearance of levonorgestrel in the plasma at steady state after oral administration</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="34.4"/>
                    <measurement group_id="O2" value="26.1" spread="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)</title>
        <description>Apparent volume of distribution during the terminal phase at steady state after oral administration</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)</title>
          <description>Apparent volume of distribution during the terminal phase at steady state after oral administration</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="729" spread="35.1"/>
                    <measurement group_id="O2" value="757" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)</title>
        <description>Apparent volume of distribution during the terminal phase at steady state after oral administration</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)</title>
          <description>Apparent volume of distribution during the terminal phase at steady state after oral administration</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" spread="41.1"/>
                    <measurement group_id="O2" value="85.0" spread="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)</title>
        <description>Terminal half-life of ethinylestradiol in plasma at steady state</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)</title>
          <description>Terminal half-life of ethinylestradiol in plasma at steady state</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>hours(h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="28.8"/>
                    <measurement group_id="O2" value="16.3" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)</title>
        <description>Terminal half-life of levonorgestrel in plasma at steady state</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)</title>
          <description>Terminal half-life of levonorgestrel in plasma at steady state</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>hours(h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="32.4"/>
                    <measurement group_id="O2" value="37.6" spread="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)</title>
        <description>Terminal rate constant of ethinylestradiol in plasma at steady state</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)</title>
          <description>Terminal rate constant of ethinylestradiol in plasma at steady state</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0454" spread="28.8"/>
                    <measurement group_id="O2" value="0.0425" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)</title>
        <description>Terminal rate constant of levonorgestrel in plasma at steady state</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)</title>
          <description>Terminal rate constant of levonorgestrel in plasma at steady state</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0189" spread="32.4"/>
                    <measurement group_id="O2" value="0.0184" spread="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)</title>
        <description>Mean residence time of ethinylestradiol in the body at steady state after oral administration</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)</title>
          <description>Mean residence time of ethinylestradiol in the body at steady state after oral administration</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>hours(h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="28.1"/>
                    <measurement group_id="O2" value="19.5" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)</title>
        <description>Mean residence time of levonorgestrel in the body at steady state after oral administration</description>
        <time_frame>Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)</title>
          <description>Mean residence time of levonorgestrel in the body at steady state after oral administration</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who took at least one dose of study medication, who provided evaluable data for at least one primary PK endpoint without important protocol violations.</population>
          <units>hours(h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" spread="33.1"/>
                    <measurement group_id="O2" value="49.6" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.</title>
        <description>Number of participants with clinically relevant abnormalities in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as adverse events.</description>
        <time_frame>Day 1 to day 17</time_frame>
        <population>Treated set (TS) included all subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.</title>
          <description>Number of participants with clinically relevant abnormalities in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as adverse events.</description>
          <population>Treated set (TS) included all subjects who took at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Tolerability</title>
        <description>Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory, bad and not assessable.</description>
        <time_frame>Within Day 24 to Day 31</time_frame>
        <population>Treated set (TS) included all subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Microgynon</title>
            <description>One tablet of Microgynon once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Microgynon Plus Empa</title>
            <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Tolerability</title>
          <description>Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory, bad and not assessable.</description>
          <population>Treated set (TS) included all subjects who took at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not assessable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>day1 to day17</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Microgynon</title>
          <description>One tablet of Microgynon once daily for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Microgynon Plus Empa</title>
          <description>One tablet of Microgynon once daily plus empa 25mg once daily for seven days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

